Nervous System News and Research

Latest Nervous System News and Research

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Life Sciences Discovery Fund announces nearly $600,000 in awards

The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions.

9 Feb 2011

Lundbeck announces second annual campaign to raise awareness on rare diseases

Today, Lundbeck announced its second annual Raise Your Hand to Fight Rare Diseases campaign in support of Rare Disease Day, a worldwide observance each year on February 28 to raise awareness of rare diseases.

8 Feb 2011

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

A digital signal processing technique long used by statisticians to analyze data is helping Houston scientists understand the roots of memory and learning, Alzheimer's and Parkinson's diseases and stroke.

8 Feb 2011

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

UCB SA, on behalf of its affiliate UCB Pharma S.A., and PDL BioPharma, today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia, and PDL's patents known as the Queen et al. patents.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Higher vitamin D levels and sun exposure linked to lower risk of multiple sclerosis

People who spend more time in the sun and those with higher vitamin D levels may be less likely to develop multiple sclerosis (MS), according to a study published in the February 8, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. MS is a chronic disease of the brain and spinal cord, usually with recurrent flare-ups of symptoms. It is often preceded by a first episode (or event) of similar symptoms lasting days to weeks.

8 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Acupuncture and exercise help women with PCOS

Acupuncture and physical exercise improve hormone levels and menstrual bleeding pattern in women with polycystic ovary syndrome (PCOS), reveals research from the University of Gothenburg, Sweden.

7 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

7 Feb 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011

Researchers trace scent signals from nose to higher centers of mouse brain

Mice know fear. And they know to fear the scent of a predator. But how do their brains quickly figure out with a sniff that a cat is nearby?

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Benefits and underutilization of ITB therapy for multiple sclerosis

A new scientific article has been published demonstrating the profound impact of spasticity on patients with multiple sclerosis and the benefits and underutilization of intrathecal baclofen (ITB) therapy from Medtronic, Inc. as a treatment option for these patients.

4 Feb 2011

Stem cells delivered intranasally improve motor function in Parkinson's disease

Stem cells, delivered intranasally, were found to substantially improve motor function in Parkinson's disease in a study co-authored by William H. Frey II, Ph.D, Director of the Alzheimer's Research Center, part of HealthPartners Research Foundation. Frey collaborated with Lusine Danielyan, MD, of University Hospital of Tubingen in Germany.

4 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Nervous System News and Research

Latest Nervous System News and Research

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Life Sciences Discovery Fund announces nearly $600,000 in awards

Lundbeck announces second annual campaign to raise awareness on rare diseases

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Higher vitamin D levels and sun exposure linked to lower risk of multiple sclerosis

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Acupuncture and exercise help women with PCOS

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Researchers trace scent signals from nose to higher centers of mouse brain

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

ECR launches sleep aid product, Zolpimist Oral Spray in the US

Benefits and underutilization of ITB therapy for multiple sclerosis

Stem cells delivered intranasally improve motor function in Parkinson's disease

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in